Last $4.10 USD
Change Today -0.11 / -2.61%
Volume 12.9K
SKBI On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 2:01 PM 10/31/14 All times are local (Market data is delayed by at least 15 minutes).

skystar bio-pharmaceutical (SKBI) Snapshot

Open
$4.22
Previous Close
$4.21
Day High
$4.22
Day Low
$4.07
52 Week High
07/3/14 - $8.22
52 Week Low
12/16/13 - $3.22
Market Cap
34.4M
Average Volume 10 Days
11.2K
EPS TTM
$1.29
Shares Outstanding
8.4M
EX-Date
--
P/E TM
3.2x
Dividend
--
Dividend Yield
--
Current Stock Chart for SKYSTAR BIO-PHARMACEUTICAL (SKBI)

Related News

No related news articles were found.

skystar bio-pharmaceutical (SKBI) Related Businessweek News

No Related Businessweek News Found

skystar bio-pharmaceutical (SKBI) Details

Skystar Bio-Pharmaceutical Company researches, develops, produces, markets, and sells veterinary healthcare and medical care products in the People’s Republic of China. The company offers micro-organism products, veterinary medicines for poultry and livestock, feed additives, and bio-pharmaceutical veterinary vaccines. It markets its products through distributers and franchise distributors, as well as directly to customers. The company is headquartered in Xi’an, the People’s Republic of China.

skystar bio-pharmaceutical (SKBI) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $121.6K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $182.5K
Compensation as of Fiscal Year 2013.

skystar bio-pharmaceutical (SKBI) Key Developments

Skystar Bio Pharmaceutical Company Presents at Aegis Capital 2014 Healthcare & Technology Conference, Sep-12-2014 09:30 AM

Skystar Bio Pharmaceutical Company Presents at Aegis Capital 2014 Healthcare & Technology Conference, Sep-12-2014 09:30 AM. Venue: The Encore at Wynn Las Vegas, 3121 Las Vegas Blvd. South, Las Vegas, NV 89109, United States.

Skystar to Launch Probiotic Supplement for Dairy Cows by End of Fiscal 2014

Skystar Bio-Pharmaceutical Company announced preparations to launch a new probiotic product for dairy cows by the end of fiscal 2014. The dairy cow probiotic is developed for the milk production industry in China and is designed to introduce Bacillus Subtilis (B. subtilis), also known as "Hay Bacillus," into the digestive tract of milk producing cows. Hay Bacillus has been proven to aid in the digestion and breakdown of hay in the animals' rumen canal. Skystar's dairy cow probiotic is expected to launch at the end of the fiscal year and is a welcome addition to Skystar's Western medicine-based line of animal husbandry products. Currently, the demand for milk outpaces domestic supply in China and as a result consumers are buying imported dairy products such as powdered milk to meet the shortfall. B. subtilis natto is produced from soybeans fermented with B. subtilis. There have been a number of major dairy experiments with good results. The conclusions have included improved milk production and milk components yield, decreased somatic cell count (a metric for milk quality) increase of total ruminal bacteria and increase of proteolytic and mylolytic bacteria. Results of trials introducing B. subtilis natto to the gut flora have demonstrated, among others: Anti-inflammatory properties; Anti-stress and fatigue, enhanced immune system, improved vaccine protection force and the protection rate; Increased milk production and milk quality; Improved digestion and absorption of feed; Improved rumen environment and rumen buffering capacity, promoting the growth and metabolism of rumen microorganisms, stable rumen pH, thereby improving rumen absorption of volatile fatty acids (VFA).

Skystar Bio Pharmaceutical Company Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014; Provides Revenue Guidance for the 2014

Skystar Bio Pharmaceutical Company announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported revenue of $14,239,605 against $11,335,145 a year ago. Income from operations was $3,367,731 against $4,546,248 a year ago. Income before provision for income taxes was $3,493,149 against $4,447,638 a year ago. Net income was $2,810,760 against $3,750,881 a year ago. Diluted earnings per share were $0.36 against basic and diluted earnings per share of $0.49 a year ago. Overall increase in revenue was primarily due to an increase in its veterinary medications sales. For the six months, the company reported revenue of $21,072,193 against $16,865,886 a year ago. Income from operations was $4,540,078 against $5,616,533 a year ago. Income before provision for income taxes was $4,898,626 against $5,481,655 a year ago. Net income was $3,786,210 against $4,463,614 a year ago. Basic and diluted earnings per share were $0.49 against $0.59 a year ago. Net cash provided by operating activities was $10,016,900 against net cash used in operating activities of $10,634,524 a year ago. The company anticipates delivering an 8% to 18% year over year increase in top line revenue for fiscal 2014 as compared to the prior year. The expected revenue range is $46 million to $50 million with gross margin of roughly 50% for fiscal 2014.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SKBI:US $4.10 USD -0.11

SKBI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
China Animal Husbandry Industry Co Ltd CNY15.37 CNY +0.05
Guangdong VTR Bio-Tech Co Ltd CNY29.40 CNY -0.18
Inner Mongolia Jinyu Group Ltd CNY36.22 CNY +0.06
Xinjiang Tecon Animal Husbandry Bio-Technology Co Ltd CNY14.08 CNY -0.24
View Industry Companies
 

Industry Analysis

SKBI

Industry Average

Valuation SKBI Industry Range
Price/Earnings 3.3x
Price/Sales 0.7x
Price/Book 0.3x
Price/Cash Flow 3.6x
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SKYSTAR BIO-PHARMACEUTICAL, please visit www.skystarbio-pharmaceutical.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.